HK1198172A1 - 具有延長的體內半衰期的因子 -聚唾液酸結合物 - Google Patents
具有延長的體內半衰期的因子 -聚唾液酸結合物Info
- Publication number
- HK1198172A1 HK1198172A1 HK14111668.2A HK14111668A HK1198172A1 HK 1198172 A1 HK1198172 A1 HK 1198172A1 HK 14111668 A HK14111668 A HK 14111668A HK 1198172 A1 HK1198172 A1 HK 1198172A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- viia
- prolonged
- poly
- life
- sialic acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6437—Coagulation factor VIIa (3.4.21.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US87521706P | 2006-12-15 | 2006-12-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1198172A1 true HK1198172A1 (zh) | 2015-03-13 |
Family
ID=39119264
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK14111668.2A HK1198172A1 (zh) | 2006-12-15 | 2014-11-19 | 具有延長的體內半衰期的因子 -聚唾液酸結合物 |
Country Status (13)
Country | Link |
---|---|
US (4) | US8637007B2 (zh) |
EP (3) | EP2101821B1 (zh) |
JP (4) | JP5876208B2 (zh) |
CN (3) | CN101557830B (zh) |
AU (1) | AU2007333049B2 (zh) |
BR (1) | BRPI0720282B8 (zh) |
CA (1) | CA2670618C (zh) |
DK (1) | DK2101821T3 (zh) |
ES (2) | ES2521490T3 (zh) |
HK (1) | HK1198172A1 (zh) |
PL (1) | PL2101821T3 (zh) |
PT (1) | PT2101821E (zh) |
WO (1) | WO2008074032A1 (zh) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7982010B2 (en) | 2006-03-31 | 2011-07-19 | Baxter International Inc. | Factor VIII polymer conjugates |
US7985839B2 (en) | 2006-03-31 | 2011-07-26 | Baxter International Inc. | Factor VIII polymer conjugates |
BRPI0708832A2 (pt) | 2006-03-31 | 2011-06-14 | Baxter Int | construÇço proteinÁcea |
US7645860B2 (en) * | 2006-03-31 | 2010-01-12 | Baxter Healthcare S.A. | Factor VIII polymer conjugates |
CA2670618C (en) * | 2006-12-15 | 2016-10-04 | Baxter International Inc. | Factor viia- (poly) sialic acid conjugate having prolonged in vivo half-life |
EP2139499A4 (en) * | 2007-04-26 | 2010-05-05 | Inspiration Biopharmaceuticals | RECOMBINANT VITAMIN K-DEPENDENT PROTEINS WITH HIGH SIALIC ACID CONTENT AND METHOD FOR THE PRODUCTION THEREOF |
US7700551B2 (en) | 2007-06-26 | 2010-04-20 | Baxter International Inc. | Hydrolysable polymeric FMOC-linker |
SI2349342T1 (sl) * | 2008-10-17 | 2018-10-30 | Baxalta GmbH | Modificirani krvni faktorji, ki obsegajo nizko stopnjo v vodi topnega polimera |
EP2398822B1 (en) | 2009-02-19 | 2013-01-02 | Novo Nordisk A/S | Modification of factor viii |
KR101912335B1 (ko) | 2009-07-27 | 2018-10-26 | 리폭센 테크놀로지즈 리미티드 | 비혈액 응고 단백질의 글리코폴리시알화 |
US8809501B2 (en) | 2009-07-27 | 2014-08-19 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
US8642737B2 (en) | 2010-07-26 | 2014-02-04 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
NZ623810A (en) | 2009-07-27 | 2015-10-30 | Lipoxen Technologies Ltd | Glycopolysialylation of non-blood coagulation proteins |
ES2597954T3 (es) | 2009-07-27 | 2017-01-24 | Baxalta GmbH | Conjugados de proteína de la coagulación sanguínea |
US8759293B2 (en) | 2009-11-13 | 2014-06-24 | Grifols Therapeutics Inc. | von Willebrand factor (vWF)-containing preparations, and methods, kits, and uses related thereto |
JP5914363B2 (ja) | 2010-02-16 | 2016-05-11 | ノヴォ ノルディスク アー/エス | 低減されたvwf結合を有する因子viii分子 |
GB201007356D0 (en) | 2010-04-30 | 2010-06-16 | Leverton Licence Holdings Ltd | Conjugated factor VIIa |
MX346271B (es) | 2010-07-30 | 2016-07-08 | Baxalta Inc | Catalizadores nucleofílicos para enlace de oxima. |
BR112013015898A2 (pt) | 2010-12-22 | 2018-06-26 | Baxter International Inc. | derivado de ácido graxo solúvel em água, e, métodos para preparar um derivado de ácido graxo e uma proteína terapêutica conjugada. |
TWI596110B (zh) | 2011-09-23 | 2017-08-21 | 諾佛 儂迪克股份有限公司 | 新穎升糖素類似物 |
US20150086524A1 (en) | 2012-04-16 | 2015-03-26 | Cantab Biopharmaceuticals Patents Limited | Optimised subcutaneous therapeutic agents |
AU2013204754C1 (en) | 2012-05-16 | 2018-10-11 | Takeda Pharmaceutical Company Limited | Nucleophilic Catalysts for Oxime Linkage |
JP2015533152A (ja) | 2012-10-15 | 2015-11-19 | ノヴォ・ノルディスク・ヘルス・ケア・アーゲー | 第vii因子コンジュゲート |
WO2014170496A1 (en) | 2013-04-18 | 2014-10-23 | Novo Nordisk A/S | Stable, protracted glp-1/glucagon receptor co-agonists for medical use |
WO2015055692A1 (en) | 2013-10-15 | 2015-04-23 | Novo Nordisk Health Care Ag | Coagulation factor vii polypeptides |
US20150158926A1 (en) | 2013-10-21 | 2015-06-11 | Opko Biologics, Ltd. | Long-acting polypeptides and methods of producing and administering same |
AR099340A1 (es) * | 2014-02-12 | 2016-07-13 | Novo Nordisk As | Conjugados del factor de coagulación ix |
RU2016144159A (ru) * | 2014-04-11 | 2018-05-11 | СиЭсЭл ЛИМИТЕД | Белок-фактор fviia с увеличенным периодом полужизни для профилактики и лечения кровотечения, и его режимы дозирования |
CN106536547A (zh) | 2014-06-04 | 2017-03-22 | 诺和诺德股份有限公司 | 用于医疗用途的glp‑1/胰高血糖素受体共激动剂 |
JP2015155469A (ja) * | 2015-06-01 | 2015-08-27 | バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated | 第fviii因子ポリマー結合体 |
HUE064463T2 (hu) * | 2016-07-11 | 2024-03-28 | Opko Biologics Ltd | Hosszantartó hatású VII. koagulációs faktor és az elõállítására vonatkozó eljárások |
JP2018115170A (ja) * | 2018-03-02 | 2018-07-26 | バクスアルタ ゲーエムベーハー | 第fviii因子ポリマー結合体 |
JP2022519586A (ja) * | 2019-02-04 | 2022-03-24 | ゼネティック バイオサイエンシーズ インコーポレイテッド | 糖ポリシアル酸化治療用タンパク質を使用する方法 |
Family Cites Families (135)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3487890A (en) | 1967-04-14 | 1970-01-06 | Boyles Bros Drilling Co | Core drilling system |
US3847890A (en) | 1971-11-01 | 1974-11-12 | A Green | Acidic monosaccharide-substituted proteins |
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4356170A (en) | 1981-05-27 | 1982-10-26 | Canadian Patents & Development Ltd. | Immunogenic polysaccharide-protein conjugates |
US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
US4970300A (en) | 1985-02-01 | 1990-11-13 | New York University | Modified factor VIII |
GR860984B (en) | 1985-04-17 | 1986-08-18 | Zymogenetics Inc | Expression of factor vii and ix activities in mammalian cells |
US5250421A (en) | 1986-01-03 | 1993-10-05 | Genetics Institute, Inc. | Method for producing factor VIII:C-type proteins |
US5198349A (en) | 1986-01-03 | 1993-03-30 | Genetics Institute, Inc. | Method for producing factor VIII:C and analogs |
JPH0387173A (ja) | 1987-09-10 | 1991-04-11 | Teijin Ltd | ヒト活性化天然型ファクター8cの製造方法及びそれに用いる形質転換体 |
US5153265A (en) | 1988-01-20 | 1992-10-06 | Cetus Corporation | Conjugation of polymer to colony stimulating factor-1 |
US4966999A (en) | 1988-06-07 | 1990-10-30 | Cytogen Corporation | Radiohalogenated compounds for site specific labeling |
US5122614A (en) | 1989-04-19 | 1992-06-16 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
SE465222C5 (sv) | 1989-12-15 | 1998-02-10 | Pharmacia & Upjohn Ab | Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning |
SE466754B (sv) | 1990-09-13 | 1992-03-30 | Berol Nobel Ab | Saett att kovalent binda biopolymerer till hydrofila ytor |
EP0513332A4 (en) | 1990-11-14 | 1993-03-17 | Cargill, Incorporated | Conjugates of poly(vinylsaccharide) with proteins for the stabilization of proteins |
CA2101918A1 (en) | 1991-03-18 | 1992-09-19 | Samuel Zalipsky | Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers |
US5846951A (en) | 1991-06-06 | 1998-12-08 | The School Of Pharmacy, University Of London | Pharmaceutical compositions |
GB9112212D0 (en) * | 1991-06-06 | 1991-07-24 | Gregoriadis Gregory | Pharmaceutical compositions |
US6037452A (en) | 1992-04-10 | 2000-03-14 | Alpha Therapeutic Corporation | Poly(alkylene oxide)-Factor VIII or Factor IX conjugate |
WO1994005332A2 (en) | 1992-09-01 | 1994-03-17 | Berlex Laboratories, Inc. | Glycolation of glycosylated macromolecules |
JP3905921B2 (ja) | 1992-10-02 | 2007-04-18 | ジェネティクス インスチチュート リミテッド ライアビリティー カンパニー | 凝固第▲viii▼因子を含む組成物及びその製造方法並びに安定剤としての界面活性剤の使用方法 |
NZ250375A (en) | 1992-12-09 | 1995-07-26 | Ortho Pharma Corp | Peg hydrazone and peg oxime linkage forming reagents and protein derivatives |
US5298643A (en) | 1992-12-22 | 1994-03-29 | Enzon, Inc. | Aryl imidate activated polyalkylene oxides |
FR2700268B1 (fr) | 1993-01-13 | 1995-03-31 | Lvmh Rech | Composition cosmétique ou pharmaceutique, notamment dermatologique, contenant un extrait de Vismia. |
AU6029594A (en) | 1993-01-15 | 1994-08-15 | Enzon, Inc. | Factor viii - polymeric conjugates |
WO1994028024A1 (en) | 1993-06-01 | 1994-12-08 | Enzon, Inc. | Carbohydrate-modified polymer conjugates with erythropoietic activity |
US5621039A (en) | 1993-06-08 | 1997-04-15 | Hallahan; Terrence W. | Factor IX- polymeric conjugates |
SE504074C2 (sv) | 1993-07-05 | 1996-11-04 | Pharmacia Ab | Proteinberedning för subkutan, intramuskulär eller intradermal administrering |
WO1996041813A2 (en) | 1994-11-09 | 1996-12-27 | Offord Robin E | Functionalized polymers for site-specific attachment |
WO1996040731A1 (en) | 1995-06-07 | 1996-12-19 | Mount Sinai School Of Medicine Of The City University Of New York | Pegylated modified proteins |
SE9503380D0 (sv) | 1995-09-29 | 1995-09-29 | Pharmacia Ab | Protein derivatives |
US5763401A (en) | 1996-07-12 | 1998-06-09 | Bayer Corporation | Stabilized albumin-free recombinant factor VIII preparation having a low sugar content |
JP2001508783A (ja) | 1997-01-29 | 2001-07-03 | ポリマスク・ファーマシューティカルズ・パブリック・リミテッド・カンパニー | Peg化法 |
EP0981548A4 (en) | 1997-04-30 | 2005-11-23 | Enzon Inc | SINGLE CHAIN PROTEINS FIXING ANTIGENS CAPABLE OF GLYCOSYLATION, PRODUCTION AND USES THEREOF |
US6183738B1 (en) | 1997-05-12 | 2001-02-06 | Phoenix Pharamacologics, Inc. | Modified arginine deiminase |
US6673575B1 (en) | 1997-12-03 | 2004-01-06 | Roche Diagnostics Gmbh | Method for preparing polypeptides with appropriate glycosilation |
US5985263A (en) | 1997-12-19 | 1999-11-16 | Enzon, Inc. | Substantially pure histidine-linked protein polymer conjugates |
CA2329768C (en) | 1998-04-27 | 2008-06-10 | Opperbas Holding B.V. | Pharmaceutical composition comprising factor viii and neutral liposomes |
CN1330675A (zh) | 1998-08-28 | 2002-01-09 | 格莱风科学公司 | 精确长度的聚酰胺链、其制备方法和其与蛋白质的缀合物 |
AU762616B2 (en) | 1998-10-16 | 2003-07-03 | Biogen Ma Inc. | Polymer conjugates of interferon beta-1a and uses |
DE19852729A1 (de) | 1998-11-16 | 2000-05-18 | Werner Reutter | Rekombinante Glycoproteine, Verfahren zu ihrer Herstellung, sie enthaltende Arzneimittel und ihre Verwendung |
PT2130554E (pt) | 1999-02-22 | 2012-11-19 | Univ Connecticut | Formulações de factor viii isentas de albumina |
US6531122B1 (en) | 1999-08-27 | 2003-03-11 | Maxygen Aps | Interferon-β variants and conjugates |
CN1309423C (zh) | 1999-11-12 | 2007-04-11 | 马克西根控股公司 | 干扰素γ偶联物 |
RU2278123C2 (ru) | 2000-02-11 | 2006-06-20 | Максиджен Холдингз Лтд. | Молекулы, подобные фактору vii или viia |
US6586398B1 (en) | 2000-04-07 | 2003-07-01 | Amgen, Inc. | Chemically modified novel erythropoietin stimulating protein compositions and methods |
EP1280548B1 (en) | 2000-05-03 | 2013-12-11 | Novo Nordisk Health Care AG | Subcutaneous administration of coagulation factor VII |
EP1282693B1 (en) | 2000-05-03 | 2010-10-20 | Novo Nordisk Health Care AG | Human coagulation factor vii variants |
CN1434726A (zh) | 2000-06-08 | 2003-08-06 | 拉卓拉药物公司 | 包含高分子量聚环氧乙烷的多价平台分子 |
US6423826B1 (en) | 2000-06-30 | 2002-07-23 | Regents Of The University Of Minnesota | High molecular weight derivatives of vitamin K-dependent polypeptides |
US7118737B2 (en) | 2000-09-08 | 2006-10-10 | Amylin Pharmaceuticals, Inc. | Polymer-modified synthetic proteins |
PL204888B1 (pl) | 2000-09-13 | 2010-02-26 | Novo Nordisk Healthcare Ag | Wariant polipeptydu czynnika VII, konstrukcja kwasu nukleinowego, rekombinowana komórka gospodarza, zwierzę transgeniczne, sposób wytwarzania wariantu polipeptydu czynnika VII, kompozycja farmaceutyczna i zastosowanie wariantu polipeptydu czynnika VII |
US6903069B2 (en) | 2000-10-02 | 2005-06-07 | Novo Nordisk Health Care A/S | Factor VII glycoforms |
DE60137525D1 (de) | 2000-10-16 | 2009-03-12 | Chugai Pharmaceutical Co Ltd | Peg-modifiziertes erythropoietin |
ES2432967T3 (es) | 2001-03-22 | 2013-12-05 | Novo Nordisk Health Care Ag | Derivados del Factor VII de coagulación |
US6913915B2 (en) | 2001-08-02 | 2005-07-05 | Phoenix Pharmacologics, Inc. | PEG-modified uricase |
US8008252B2 (en) * | 2001-10-10 | 2011-08-30 | Novo Nordisk A/S | Factor VII: remodeling and glycoconjugation of Factor VII |
US7214660B2 (en) | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
US7795210B2 (en) | 2001-10-10 | 2010-09-14 | Novo Nordisk A/S | Protein remodeling methods and proteins/peptides produced by the methods |
EP2292271A3 (en) | 2001-10-10 | 2011-09-14 | BioGeneriX AG | Remodelling and glycoconjugation of an antibody |
KR100948532B1 (ko) | 2001-11-07 | 2010-03-23 | 넥타르 테라퓨틱스 | 분지형 중합체 및 그의 공액체 |
EP1461445B1 (en) | 2001-11-28 | 2008-08-20 | Neose Technologies, Inc. | Glycoprotein remodeling using endoglycanases |
JP2005510229A (ja) | 2001-11-28 | 2005-04-21 | ネオーズ テクノロジーズ, インコーポレイテッド | アミダーゼを用いる糖タンパク質のリモデリング |
MXPA04012496A (es) * | 2002-06-21 | 2005-09-12 | Novo Nordisk Healthcare Ag | Glicoformos del factor vii pegilados. |
AU2003240439B2 (en) * | 2002-06-21 | 2009-05-21 | Novo Nordisk Health Care Ag | Pegylated factor VII glycoforms |
US7122189B2 (en) | 2002-08-13 | 2006-10-17 | Enzon, Inc. | Releasable polymeric conjugates based on aliphatic biodegradable linkers |
US7087229B2 (en) | 2003-05-30 | 2006-08-08 | Enzon Pharmaceuticals, Inc. | Releasable polymeric conjugates based on aliphatic biodegradable linkers |
WO2004024776A1 (en) | 2002-09-11 | 2004-03-25 | Fresenius Kabi Deutschland Gmbh | Method of producing hydroxyalkyl starch derivatives |
US20040062748A1 (en) | 2002-09-30 | 2004-04-01 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof |
KR101025143B1 (ko) | 2002-12-31 | 2011-04-01 | 넥타르 테라퓨틱스 | 가수분해상으로 안정한 말레이미드-종결 중합체 |
AU2003300139B2 (en) | 2002-12-31 | 2008-08-28 | Nektar Therapeutics | Maleamic acid polymer derivatives and their bioconjugates |
HUE058897T2 (hu) | 2003-02-26 | 2022-09-28 | Nektar Therapeutics | Polimer VIII-as faktor egység konjugátumok |
US7691603B2 (en) * | 2003-04-09 | 2010-04-06 | Novo Nordisk A/S | Intracellular formation of peptide conjugates |
JP2007501811A (ja) | 2003-08-08 | 2007-02-01 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | 治療的な関心対象のタンパク質に対する遅延分子の選択的な化学物質接合のためのガラクトースオキシダーゼの使用。 |
EP1653991A2 (en) | 2003-08-08 | 2006-05-10 | Fresenius Kabi Deutschland GmbH | Conjugates of a polymer and a protein linked by an oxime linking group |
US7807824B2 (en) | 2003-08-12 | 2010-10-05 | Lipoxen Technologies Limited | Sialic acid derivatives for protein derivatisation and conjugation |
WO2005016973A1 (en) | 2003-08-12 | 2005-02-24 | Lipoxen Technologies Limited | Polysialic acid derivatives |
EP1673453A2 (en) | 2003-10-07 | 2006-06-28 | Novo Nordisk Health Care AG | Hybrid molecules having factor vii/viia activity |
JP4738346B2 (ja) | 2003-12-03 | 2011-08-03 | ノヴォ ノルディスク アー/エス | GlycoPEG化された第IX因子 |
KR101439880B1 (ko) | 2004-01-08 | 2014-09-12 | 라티오팜 게엠베하 | 펩티드의 오-결합형 글리코실화 |
KR100651220B1 (ko) | 2004-06-29 | 2006-11-29 | 씨제이 주식회사 | L-메씨오닌 생산 균주 및 상기 균주를 이용한l-메씨오닌의 생산방법 |
AU2005261277A1 (en) | 2004-07-14 | 2006-01-19 | Mali Arel | Feeding bottles |
US20090292110A1 (en) | 2004-07-23 | 2009-11-26 | Defrees Shawn | Enzymatic modification of glycopeptides |
JP2008507990A (ja) | 2004-08-02 | 2008-03-21 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | Fviiの抱合体 |
EP1776389B1 (en) | 2004-08-12 | 2016-06-29 | Lipoxen Technologies Limited | Sialic acid derivatives |
EP1824988B1 (en) | 2004-11-12 | 2017-04-19 | Bayer HealthCare LLC | Site-directed modification of fviii |
CN101163506B (zh) * | 2004-12-27 | 2012-09-26 | 巴克斯特国际公司 | 聚合物-von Willebrand因子偶联物 |
EP1838332A1 (en) | 2005-01-06 | 2007-10-03 | Neose Technologies, Inc. | Glycoconjugation using saccharyl fragments |
WO2006090119A1 (en) * | 2005-02-23 | 2006-08-31 | Lipoxen Technologies Limited | Activated sialic acid derivatives for protein derivatisation and conjugation |
AU2006222187A1 (en) * | 2005-03-11 | 2006-09-14 | Fresenius Kabi Deutschland Gmbh | Production of bioactive glycoproteins from inactive starting material by conjugation with hydroxyalkylstarch |
JP5216580B2 (ja) | 2005-05-25 | 2013-06-19 | ノヴォ ノルディスク アー/エス | グリコペグ化第ix因子 |
WO2006134173A2 (en) | 2005-06-17 | 2006-12-21 | Novo Nordisk Health Care Ag | Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine |
US20090017007A1 (en) | 2005-08-26 | 2009-01-15 | Maxygen Holdings Ltd. | Liquid factor vii composition |
US7390786B2 (en) | 2005-12-21 | 2008-06-24 | Wyeth | Protein formulations with reduced viscosity and uses thereof |
US7985839B2 (en) | 2006-03-31 | 2011-07-26 | Baxter International Inc. | Factor VIII polymer conjugates |
BRPI0708832A2 (pt) | 2006-03-31 | 2011-06-14 | Baxter Int | construÇço proteinÁcea |
US7645860B2 (en) | 2006-03-31 | 2010-01-12 | Baxter Healthcare S.A. | Factor VIII polymer conjugates |
US7982010B2 (en) | 2006-03-31 | 2011-07-19 | Baxter International Inc. | Factor VIII polymer conjugates |
US20090285780A1 (en) | 2006-05-24 | 2009-11-19 | Chyi Lee | Peg linker compounds and biologically active conjugates thereof |
JP2007319283A (ja) * | 2006-05-31 | 2007-12-13 | Nippon Sherwood Medical Industries Ltd | 医療用バッグ |
US7939632B2 (en) | 2006-06-14 | 2011-05-10 | Csl Behring Gmbh | Proteolytically cleavable fusion proteins with high molar specific activity |
ES2565180T3 (es) | 2006-07-13 | 2016-04-01 | Serum Institute Of India Ltd, | Proceso para la preparación de ácido polisiálico de gran pureza |
KR101400105B1 (ko) | 2006-07-25 | 2014-06-19 | 리폭센 테크놀로지즈 리미티드 | N-말단 폴리시알화 |
WO2008057683A2 (en) | 2006-10-03 | 2008-05-15 | Novo Nordisk A/S | Methods for the purification of polypeptide conjugates |
CA2670618C (en) | 2006-12-15 | 2016-10-04 | Baxter International Inc. | Factor viia- (poly) sialic acid conjugate having prolonged in vivo half-life |
US20100143326A1 (en) | 2007-01-03 | 2010-06-10 | Novo Nordisk Healthcare A/G | SUBCUTANEOUS ADMINISTRATION OF COAGULATION FACTOR VIIa-RELATED POLYPEPTIDES |
WO2008119815A1 (en) | 2007-04-02 | 2008-10-09 | Novo Nordisk A/S | Subcutaneous administration of coagulation factor ix |
US7700551B2 (en) | 2007-06-26 | 2010-04-20 | Baxter International Inc. | Hydrolysable polymeric FMOC-linker |
EP2173759A4 (en) | 2007-07-03 | 2014-01-29 | Childrens Hosp & Res Ct Oak | OLIGOSIALIC ACID DERIVATIVES, METHODS OF MANUFACTURE AND IMMUNOLOGICAL USES |
ES2597849T3 (es) | 2007-10-09 | 2017-01-23 | Polytherics Limited | Proteínas y péptidos conjugados novedosos |
US20100286067A1 (en) | 2008-01-08 | 2010-11-11 | Biogenerix Ag | Glycoconjugation of polypeptides using oligosaccharyltransferases |
CN103497246B (zh) | 2008-02-27 | 2016-08-10 | 诺沃—诺迪斯克有限公司 | 缀合的因子viii分子 |
MX2010011672A (es) | 2008-04-24 | 2011-03-02 | Celtic Pharma Peg Ltd | Conjugados del factor ix con vidas medias extendidas. |
CN102083459A (zh) | 2008-05-23 | 2011-06-01 | 诺沃-诺迪斯克保健股份有限公司 | 包括含有peg化的gla-结构域的蛋白质的低粘度组合物 |
JP2011520999A (ja) | 2008-05-23 | 2011-07-21 | ノボ ノルディスク ヘルス ケア アーゲー | 高濃度の芳香族保存料を有するペグ官能化セリンプロテアーゼの製剤 |
CA2726942A1 (en) | 2008-06-04 | 2009-12-10 | Bayer Healthcare Llc | Fviii muteins for treatment of von willebrand disease |
KR101763559B1 (ko) | 2008-07-21 | 2017-08-14 | 폴리테릭스 리미티드 | 생물학적 분자의 컨쥬게이팅을 위한 신규한 시약 및 방법 |
EP2352515A4 (en) | 2008-11-03 | 2012-04-25 | Bayer Healthcare Llc | METHOD FOR TREATING HEMOPHILIA |
EP2387413A4 (en) | 2009-01-19 | 2015-12-23 | Bayer Healthcare Llc | PROTEIN CONJUGATE WITH AN ENDOPEPTIDASE-SPLICABLE BIOPROTEKTIVES PART |
EP2398822B1 (en) | 2009-02-19 | 2013-01-02 | Novo Nordisk A/S | Modification of factor viii |
US9005598B2 (en) | 2009-03-04 | 2015-04-14 | Polytherics Limited | Conjugated proteins and peptides |
US20100330033A1 (en) | 2009-04-16 | 2010-12-30 | Nian Wu | Protein-carrier conjugates |
GB0908393D0 (en) | 2009-05-15 | 2009-06-24 | Almac Sciences Scotland Ltd | Labelling method |
ES2597954T3 (es) | 2009-07-27 | 2017-01-24 | Baxalta GmbH | Conjugados de proteína de la coagulación sanguínea |
KR101912335B1 (ko) | 2009-07-27 | 2018-10-26 | 리폭센 테크놀로지즈 리미티드 | 비혈액 응고 단백질의 글리코폴리시알화 |
JP2013500726A (ja) | 2009-07-31 | 2013-01-10 | バイエル・ヘルスケア・エルエルシー | 改変第ix因子ポリペプチドおよびその使用 |
DE102009028526A1 (de) | 2009-08-13 | 2011-02-24 | Leibniz-Institut Für Polymerforschung Dresden E.V. | Verfahren zur Modifikation und Funktionalisierung von Sacchariden |
EP2480578A4 (en) | 2009-09-25 | 2013-04-17 | Vybion Inc | MODIFICATION OF POLYPEPTIDE |
WO2011064247A1 (en) | 2009-11-24 | 2011-06-03 | Novo Nordisk Health Care Ag | Method of purifying pegylated proteins |
JP5914363B2 (ja) | 2010-02-16 | 2016-05-11 | ノヴォ ノルディスク アー/エス | 低減されたvwf結合を有する因子viii分子 |
GB201007357D0 (en) | 2010-04-30 | 2010-06-16 | Leverton Licence Holdings Ltd | Conjugated factor VIII |
GB201007356D0 (en) | 2010-04-30 | 2010-06-16 | Leverton Licence Holdings Ltd | Conjugated factor VIIa |
WO2012068134A1 (en) | 2010-11-15 | 2012-05-24 | Biogen Idec Inc. | Enrichment and concentration of select product isoforms by overloaded bind and elute chromatography |
MY180714A (en) | 2011-07-08 | 2020-12-07 | Bioverativ Therapeutics Inc | Factor viii chimeric and hybrid polypeptides, and methods of use thereof |
-
2007
- 2007-12-14 CA CA2670618A patent/CA2670618C/en active Active
- 2007-12-14 AU AU2007333049A patent/AU2007333049B2/en active Active
- 2007-12-14 EP EP07865679.0A patent/EP2101821B1/en active Active
- 2007-12-14 EP EP17196565.0A patent/EP3323430A1/en not_active Withdrawn
- 2007-12-14 CN CN200780046301.6A patent/CN101557830B/zh active Active
- 2007-12-14 WO PCT/US2007/087553 patent/WO2008074032A1/en active Application Filing
- 2007-12-14 ES ES07865679.0T patent/ES2521490T3/es active Active
- 2007-12-14 JP JP2009541613A patent/JP5876208B2/ja active Active
- 2007-12-14 BR BRPI0720282A patent/BRPI0720282B8/pt active IP Right Grant
- 2007-12-14 CN CN201610304880.0A patent/CN105838699A/zh active Pending
- 2007-12-14 DK DK07865679.0T patent/DK2101821T3/da active
- 2007-12-14 PL PL07865679T patent/PL2101821T3/pl unknown
- 2007-12-14 US US11/956,634 patent/US8637007B2/en active Active
- 2007-12-14 PT PT78656790T patent/PT2101821E/pt unknown
- 2007-12-14 CN CN201310698649.0A patent/CN103804489A/zh active Pending
- 2007-12-14 EP EP12004951.5A patent/EP2532369B1/en active Active
- 2007-12-14 ES ES12004951.5T patent/ES2655639T3/es active Active
-
2010
- 2010-09-08 US US12/877,425 patent/US20110064714A1/en not_active Abandoned
-
2012
- 2012-12-25 JP JP2012281272A patent/JP2013060462A/ja active Pending
-
2013
- 2013-12-20 US US14/136,328 patent/US20140186323A1/en not_active Abandoned
-
2014
- 2014-11-19 HK HK14111668.2A patent/HK1198172A1/zh unknown
-
2015
- 2015-06-16 JP JP2015121340A patent/JP2015163650A/ja not_active Withdrawn
- 2015-11-19 US US14/946,286 patent/US10251941B2/en active Active
-
2017
- 2017-05-29 JP JP2017105504A patent/JP2017141305A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1198172A1 (zh) | 具有延長的體內半衰期的因子 -聚唾液酸結合物 | |
HK1246200A1 (zh) | β-葡糖苷酸藥物連接子綴合物 | |
HK1198485A1 (zh) | 分子綴合物 | |
EP1961772A4 (en) | CATIONIZED HYALURONIC ACID | |
EP2144600A4 (en) | POLY (AMINIC ACID) TARGET MOLECULES | |
IL184824A0 (en) | Infusion delivery system | |
HK1136019A1 (zh) | 用於顯示器框架的連接器 | |
GB0617191D0 (en) | Improvements in pharmaceutical compositions | |
GB0608444D0 (en) | Dialysis | |
EP2114145A4 (en) | MEANS FOR PROMOTING PHENYL ALKYL CYCLOXYLIC ACID | |
EP1834652A4 (en) | PREPARATION FOR DIALYSIS | |
GB2426875B (en) | Connector fitting structure | |
EP2052723A4 (en) | STABLE LYOPHILIZED PREPARATION | |
EP1948151A4 (en) | COMPOSITIONS USED FOR PERITONEAL DIALYSIS | |
GB0610866D0 (en) | Novel in vivo imaging compounds | |
GB2425534A8 (en) | Epsilon poly-L-lysine-nucleic acid complex | |
EP2100611A4 (en) | MEANS FOR IMPROVING GLUCOSE-METABOLISM | |
ME02948B (me) | Rastvor za peritonealnu dijalizu koji sadrži karnitin i ima poboljšanu biokompatibilnost | |
EP2042513A4 (en) | Galectin-9-POLYMER CONJUGATE | |
GB2423195B (en) | Improvements in or relating to connectors | |
GB0517043D0 (en) | Improvements in pharmaceutical compositions | |
GB0516842D0 (en) | Home delivery unit | |
TWM291636U (en) | card-edge connector | |
AU307609S (en) | Bar connector base | |
IL205358A0 (en) | In vivo suture assemblies |